{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"112"}],"units":"Participants"}],"description":"A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in deaths, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect and other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication.","groups":[{"description":"Participants received CZP sc as a fixed dose based on their body weight Q2W or Q4W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.","id":"OG000","title":"Any CZP Dose - Weight Group: 10 - <20 kg"},{"description":"Participants received CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.","id":"OG001","title":"Any CZP Dose - Weight Group: 20 - <40 kg"},{"description":"Participants received CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.","id":"OG002","title":"Any CZP Dose - Weight Group: >=40 kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Set (SS) consisted of all study participants in the Enrolled Set (ES) who have received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)","title":"Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the Study","type":"PRIMARY","unitOfMeasure":"Participants"}